Last reviewed · How we verify

DTwP-HepB-Hib-IPV vaccine

Sanofi Pasteur, a Sanofi Company · Phase 3 active Biologic

DTwP-HepB-Hib-IPV vaccine is a vaccine Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 3 development for Primary immunization against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, and poliomyelitis in infants and children. Also known as: EasySix™.

This pentavalent vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, and poliomyelitis.

This pentavalent vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, and poliomyelitis. Used for Primary immunization against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, and poliomyelitis in infants and children.

At a glance

Generic nameDTwP-HepB-Hib-IPV vaccine
Also known asEasySix™
SponsorSanofi Pasteur, a Sanofi Company
Drug classvaccine
ModalityBiologic
Therapeutic areaImmunology
PhasePhase 3

Mechanism of action

DTwP-HepB-Hib-IPV is a combination vaccine containing inactivated toxoids (diphtheria and tetanus), whole-cell pertussis bacteria, hepatitis B surface antigen, Haemophilus influenzae type b conjugate, and inactivated poliovirus antigens. Upon administration, these antigens trigger both humoral (antibody) and cell-mediated immune responses, providing protection against these six infectious diseases. The vaccine is designed for primary immunization in infants and young children.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about DTwP-HepB-Hib-IPV vaccine

What is DTwP-HepB-Hib-IPV vaccine?

DTwP-HepB-Hib-IPV vaccine is a vaccine drug developed by Sanofi Pasteur, a Sanofi Company, indicated for Primary immunization against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, and poliomyelitis in infants and children.

How does DTwP-HepB-Hib-IPV vaccine work?

This pentavalent vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, and poliomyelitis.

What is DTwP-HepB-Hib-IPV vaccine used for?

DTwP-HepB-Hib-IPV vaccine is indicated for Primary immunization against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, and poliomyelitis in infants and children.

Who makes DTwP-HepB-Hib-IPV vaccine?

DTwP-HepB-Hib-IPV vaccine is developed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).

Is DTwP-HepB-Hib-IPV vaccine also known as anything else?

DTwP-HepB-Hib-IPV vaccine is also known as EasySix™.

What drug class is DTwP-HepB-Hib-IPV vaccine in?

DTwP-HepB-Hib-IPV vaccine belongs to the vaccine class. See all vaccine drugs at /class/vaccine.

What development phase is DTwP-HepB-Hib-IPV vaccine in?

DTwP-HepB-Hib-IPV vaccine is in Phase 3.

What are the side effects of DTwP-HepB-Hib-IPV vaccine?

Common side effects of DTwP-HepB-Hib-IPV vaccine include Injection site reactions (pain, redness, swelling), Fever, Irritability, Drowsiness.

Related